Indeed, we demonstrated that a lung adenocarcinoma patient with ERBB2 amplification and harboring CDK12-G879V mutation responded to HER2-directed targeted therapy in combination with standard chemotherapy that explored the vulnerability of impaired DNA damage repair caused by the CDK12-G879V mutation [18]. Here, ERBB2 is linked to lung adenocarcinoma.